Next Article in Journal
Alphaherpesvirus Vaccines
Previous Article in Journal
Aquatic Viruses and Climate Change
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 41
Issue 1
10.21775/cimb.041.381
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Current Issues in Molecular Biology is published by MDPI from Volume 43 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Caister Press.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Oncolytic HSV Vectors and Anti-Tumor Immunity

by
Joseph C. Glorioso
1,*,
Justus B. Cohen
1,
William F. Goins
1,
Bonnie Hall
1,
Joseph W. Jackson
1,
Gary Kohanbash
2,
Nduka Amankulor
2,
Balveen Kaur
3,
Michael A. Caligiuri
4,
E. Antonio Chiocca
5,
Eric C. Holland
6 and
Christophe Quéva
7
1
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
2
Department of Neurological Surgery, Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
3
Department of Neurosurgery, McGovern Medical School at UTHealth, Houston, TX 77030, USA
4
City of Hope Medical Center, Duarte, CA 91010, USA
5
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
6
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98195, USA
7
Oncorus Inc., Cambridge, MA 02142, USA
*
Author to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2021, 41(1), 381-468; https://doi.org/10.21775/cimb.041.381
Submission received: 5 June 2020 / Revised: 11 July 2020 / Accepted: 15 August 2020 / Published: 17 September 2020
Versions Notes

Abstract

The therapeutic promise of oncolytic viruses (OVs) rests on their ability to both selectively kill tumor cells and induce anti-tumor immunity. The potential of tumors to be recognized and eliminated by an effective anti-tumor immune response has been spurred on by the discovery that immune checkpoint inhibition can overcome tumor-specific cytotoxic T cell (CTL) exhaustion and provide durable responses in multiple tumor indications. OV-mediated tumor destruction is now recognized as a powerful means to assist in the development of anti-tumor immunity for two important reasons: (i) OVs, through the elicitation of an anti-viral response and the production of type I interferon, are potent stimulators of inflammation and can be armed with transgenes to further enhance anti-tumor immune responses; and (ii) lytic activity can promote the release of tumor-associated antigens (TAAs) and tumor neoantigens that function as in situ tumor-specific vaccines to elicit adaptive immunity. Oncolytic herpes simplex viruses (oHSVs) are among the most widely studied OVs for the treatment of solid malignancies, and Amgen's oHSV Imlygic® for the treatment of melanoma is the only OV approved in major markets. Here we describe important biological features of HSV that make it an attractive OV, clinical experience with HSV-based vectors, and strategies to increase applicability to cancer treatment.

Share and Cite

MDPI and ACS Style

Glorioso, J.C.; Cohen, J.B.; Goins, W.F.; Hall, B.; Jackson, J.W.; Kohanbash, G.; Amankulor, N.; Kaur, B.; Caligiuri, M.A.; Chiocca, E.A.; et al. Oncolytic HSV Vectors and Anti-Tumor Immunity. Curr. Issues Mol. Biol. 2021, 41, 381-468. https://doi.org/10.21775/cimb.041.381

AMA Style

Glorioso JC, Cohen JB, Goins WF, Hall B, Jackson JW, Kohanbash G, Amankulor N, Kaur B, Caligiuri MA, Chiocca EA, et al. Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology. 2021; 41(1):381-468. https://doi.org/10.21775/cimb.041.381

Chicago/Turabian Style

Glorioso, Joseph C., Justus B. Cohen, William F. Goins, Bonnie Hall, Joseph W. Jackson, Gary Kohanbash, Nduka Amankulor, Balveen Kaur, Michael A. Caligiuri, E. Antonio Chiocca, and et al. 2021. "Oncolytic HSV Vectors and Anti-Tumor Immunity" Current Issues in Molecular Biology 41, no. 1: 381-468. https://doi.org/10.21775/cimb.041.381

APA Style

Glorioso, J. C., Cohen, J. B., Goins, W. F., Hall, B., Jackson, J. W., Kohanbash, G., Amankulor, N., Kaur, B., Caligiuri, M. A., Chiocca, E. A., Holland, E. C., & Quéva, C. (2021). Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology, 41(1), 381-468. https://doi.org/10.21775/cimb.041.381

Article Metrics

Back to TopTop